Search Result

Results for "

SSTRs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Somatostatin Receptor (70) Apoptosis (2) Arrestin (1) Calcium Channel (1) CD3 (1) Dopamine Receptor (1) Drug Derivative (1) G protein-coupled Bile Acid Receptor 1 (1) GHSR (1) P-glycoprotein (1) Peptide-Drug Conjugates (PDCs) (1) Potassium Channel (1) PSMA (2) Radionuclide-Drug Conjugates (RDCs) (13) Reference Standards (2) Small Interfering RNA (siRNA) (15)
By Research Areas:	Cancer (25) Cardiovascular Disease (3) Endocrinology (12) Inflammation/Immunology (5) Metabolic Disease (18) Neurological Disease (16)
Oligonucleotides:	Rat Pre-designed siRNA Sets (5) Mouse Pre-designed siRNA Sets (5) Human Pre-designed siRNA Sets (5) siRNAs (15)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Oligonucleotides

Targets Recommended: Somatostatin Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106033

Edotreotide 2 Publications Verification DOTATOC; SDZ-SMT 487; SMT 487	Radionuclide-Drug Conjugates (RDCs)	Cancer
Edotreotide is a ligand that selectively targets *SSTR2* and can competitively bind to the receptor. Edotreotide mediates the targeted delivery, while modificated with radionuclides (such as ⁹⁰Y, ¹⁷⁷Lu, and ⁶⁸Ga) to SSTR-positive tumors and induces tumor cell apoptosis by releasing β rays. Edotreotide has strong tumor targeting and precise killing activity. Edotreotide is used in the synthesis of radionuclide-drug conjugates (RDCs) and is widely used in the field of neuroendocrine tumors (such as metastatic carcinoids, lung and thymus NETs) .

HY-P5128

DOTA-JR11 1 Publications Verification Satoreotide tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P3954

Somatostatin-28 (sheep, human rat mouse)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .

HY-P5126

DOTA-LM3 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting *SSTR2* binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Neurological Disease Cancer
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor *SSTR2* with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 does not trigger the internalization of *SSTR2* and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-139347

Mazisotine LY3556050; CNTX-0290	Somatostatin Receptor	Neurological Disease
Mazisotine (CNTX-0290) is an orally active, non-opioid somatostatin receptor 4 (SSTR4) agonist with an EC₅₀ of 4.7 nM. Mazisotine exerts significant analgesic effects in various nociceptive (inflammatory, osteoarthritic) and neuropathic pain models. Mazisotine can be used for pain research .

HY-102037

SSTR5 antagonist 1	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC₅₀s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively .

HY-P10137

Satoreotide JR11	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
Satoreotide (JR11) is a *SSTR2* antagonist. Satoreotide is usually conjugated with radiolabeled chelators used in neuroendocrine tumor imaing .

HY-13466

MK-4256 3 Publications Verification	Somatostatin Receptor	Metabolic Disease Endocrinology
MK-4256 is a potent and selective *SSTR3* antagonist with IC₅₀s of 0.66 nM and 0.36 nM in human and mouse receptor binding assays, respectively.

HY-P1201

Cyclosomatostatin 1 Publications Verification	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P5126A

DOTA-LM3 TFA 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-105172

TT-232 CAP-232; TLN-232	Somatostatin Receptor	Inflammation/Immunology Cancer
TT-232 (CAP-232), a somatostatin derivative, is a peptide *SSTR1/SSTR4* agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent .

HY-106103

Seglitide MK-678; L-363586	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of *SSTR₁₄, SSTR₂₅, and SSTR₂₈*. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes .

HY-114191B

SSTR5 antagonist 2 hydrochloride	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of type 2 diabetes mellitus (T2DM) .

HY-P1212

Cortistatin 14 (mouse, rat) CST-14 (mouse, rat)	Somatostatin Receptor	Neurological Disease
Cortistatin 14, mouse, rat (CST-14, human, rat), a neuropeptide with neuronal depressant and sleep modulating properties, can bind to all five cloned somatostatin receptors (SSTRs) and ghrelin receptor to exert its biological activities and co-exists with GABA within the cortex and hippocampus .

HY-P3124A

BIM-23190 hydrochloride	Somatostatin Receptor	Cancer
BIM-23190 hydrochloride, a somatostatin analog, a selective SSRT2 and SSRT5 agonist, exhibits K_i values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly .

HY-142699

SSTR4 agonist 2	Somatostatin Receptor	Inflammation/Immunology
SSTR4 agonist 2 is a potent agonist of somatostatin receptor subtype 4 (SSTR4). SSTR4 pathway inhibits nociceptive and inflammatory processes. SSTR4 agonist 2 has the potential for the research of medical disorders related to SSTR4 (extracted from patent WO2014184275A1, compound 107) .

HY-163317A

MMC(TMZ)-TOC TFA	Somatostatin Receptor	Cancer
MMC(TMZ)-TOC TFA has high binding affinity and selectivity for somatostatin receptor subtype-2 (SSTR2). MMC(TMZ)-TOC TFA targets delivery of TMZ to SSTR2-positive tumor cells. MMC(TMZ)-TOC TFA can be used for the research of cancer .

HY-P10741

DOTA-EB-TATE	Radionuclide-Drug Conjugates (RDCs) Peptide-Drug Conjugates (PDCs) Somatostatin Receptor	Cancer
DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P1139

Cortistatin-8 PCFWKTCK	GHSR	Metabolic Disease
Cortistatin-8 (CST-8; PCFWKTCK), a neuropeptide, is a GHS-R1a antagonist by counteracting the response of ghrelin on gastric acid secretion. Cortistatin-8 can modulate GH release from somatotroph cells. Cortistatin-8 is a synthetic CST-analogue devoid of any binding affinity to SST-R but capable to bind the GHS-R1a. Cortistatin-8 can exert antagonistic effects on ghrelin actions either in vitro or in vivo in animals .

HY-106103A

Seglitide acetate MK 678 acetate; L 36358 acetate	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of *SSTR₁₄, SSTR₂₅, and SSTR₂₈*. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes .

HY-142701

SSTR4 agonist 4	Somatostatin Receptor	Neurological Disease
SSTR4 agonist 4 is a potent agonist of *SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR*4 agonist 4 has the potential for the research of pain (extracted from patent WO2021233428A1, compound 14) .

HY-P0024A

Veldoreotide TFA DG3173 TFA; PTR-3173 TFA	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) TFA a somatostatin analogue, binds to and activate the *somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide TFA inhibits growth hormone (GH)* secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-P3124

BIM-23190	Somatostatin Receptor	Cancer
BIM-23190, a somatostatin analog, a selective *SSTR2* and *SSTR5* agonist, exhibits K_i values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly .

HY-177493

SSTR3 Agonist-1	Somatostatin Receptor	Others
SSTR3 Agonist-1 (Compound EX 38) is an orally active *SSTR3* agonist, with an EC₅₀ of 0.14 nM. SSTR3 Agonist-1 reduces the kidney cystic index. SSTR3 Agonist-1 can be used in the research of autosomal dominant polycystic kidney disease .

HY-P3618

Cortistatin-29 (reduced)	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC₅₀ values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .

HY-P3294

Onzigolide BIM-23A760; TBR-760	Dopamine Receptor Somatostatin Receptor	Neurological Disease Cancer
Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors .

HY-P0024

Veldoreotide DG3173; PTR-3173	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the *somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH)* secretion in adenomas compared withOctreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-P2434

AP102	Somatostatin Receptor	Neurological Disease Metabolic Disease Cancer
AP102 is a dual *SSTR2/SSTR5*-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to *SSTR2* and *SSTR5* (IC₅₀: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .

HY-177493A

SSTR3 agonist-1 TFA	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR3 agonist-1 TFA is a potent, orally active, and selective *SSTR3* agnoist (EC₅₀ =0.14 nM). SSTR3 agonist-1 TFA binds to SSTR3 receptor to inhibit cAMP activity. SSTR3 agonist-1 TFA decreases kidney weight and kidney cystic index (KCI) in a mouse model of autosomal dominant polycystic kidney disease (ADPKD). SSTR3 agonist-1 TFA can be used for ADPKD research .

HY-P4555

(D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide	Somatostatin Receptor	Neurological Disease
(D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide (Compound 4) is a somatostatin analog with K_ds of 0.61, 11.05, 23.5, 1200 and >1000 nM for *SSTR5, SSTR3, SSTR2, SSTR1* and *SSTR4*, respectively .

HY-172147

SSTR4 agonist 5	Somatostatin Receptor	Neurological Disease
SSTR4 agonist 5 (Compound 5) is the orally active agonist for somatostatin receptor 4 (SSTR4) with an EC₅₀ of 0.228 nM. SSTR4 agonist 5 exhibits good stability in human/rat liver microsomes. SSTR4 agonist 5 inhibits mechanical hyperalgesia in rat models .

HY-160176

SSTR5 antagonist 6	Somatostatin Receptor	Metabolic Disease
SSTR5 antagonist 6 is an orally active somatostatin receptor subtype 5 (SSTR5) antagonist with an IC₅₀ of 24 nM. SSTR5 antagonist 6 can be used in the study of type 2 diabetes .

HY-142700

SSTR4 agonist 3	Somatostatin Receptor	Neurological Disease
SSTR4 agonist 3 is a potent agonist of *SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR*4 agonist 3 has the potential for the research of pain (extracted from patent WO2021233427A1, compound 14) .

HY-12819

MK-1421	Somatostatin Receptor	Metabolic Disease Endocrinology
MK-1421 is a potent and selective *sstr3* antagonist. MK-1421 regulates insulin secretion by binding to the *sstr3*. MK-1421 can be used in the research of type 2 diabetes .

HY-P2545

[Tyr1]-Somatostatin-14	Somatostatin Receptor	Endocrinology
[Tyr1]-Somatostatin-14 could binds to *SSTR2* .

HY-159825

Branosotine	Somatostatin Receptor	Endocrinology
Branosotine (compound 1-1) is a potent agonist of somatostatin receptor (SSTR2), with the EC₅₀ of ＜0.1 nM .

HY-114133

Depreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
Depreotide is a nove tumor tarcer, can be complexed with technetium-99m ( ^99mTc-depreotide) for optimal imaging properties. ^99mTc-depreotide somatostain receptor imaging has been playing an important role in medical diagnosis research . Depreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5362A

NODAGA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor *SSTR2* with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of *SSTR2* and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 TFA can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-Z15823

(R)-Verapamil Dexverapamil	Calcium Channel Potassium Channel Somatostatin Receptor Arrestin Apoptosis P-glycoprotein	Metabolic Disease Inflammation/Immunology
(R)-Verapamil (Dexverapamil) is an optically enantiomer of the oral-active Verapamil (HY-14275). (R)-Verapamil has a relatively low affinity for L-type calcium channels (Ca_v1.2) (IC₅₀ > 300 μM), and its IC₅₀ for sodium channels (sodium channel) is 3.19 μM. (R)-Verapamil exhibits *SSTR2* agonistic activity, with an EC₅₀ of 1.3 μM. (R)-Verapamil significantly downregulates the expression of TXNIP protein in diabetic mouse models and significantly inhibits β-cell apoptosis (apoptosis), effectively controlling blood sugar. (R)-Verapamil can be used as a PET tracer for the function of P-glycoprotein (P-gp) .

HY-P2150

Cortistatin-29 (rat)	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC₅₀ values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .

HY-157303

SSTR5 antagonist 3	Somatostatin Receptor	Cardiovascular Disease
SSTR5 antagonist 3 (Compound 23) is an orally active somatostatin receptor subtype 5 (SSTR5) antagonist with low hERG inhibition. SSTR5 antagonist 3 exhibits potency with IC₅₀ values of 2.8 nM and 1.4 nM in human and mouse, respectively. SSTR5 antagonist 3 can be used for the research of anti-gallstone .

HY-P4100

*Cyclic SSTR* agonist octreotide**	Somatostatin Receptor	Others
Cyclic SSTR agonist octreotide is a Octreotide (HY-P0036), serving as the cyclic Somatostatin Receptor *SSTR* agonist .

HY-163317

MMC(TMZ)-TOC	Somatostatin Receptor	Cancer
MMC(TMZ)-TOC has high binding affinity and selectivity for somatostatin receptor subtype-2 (SSTR2). MMC(TMZ)-TOC targets delivery of TMZ to SSTR2-positive tumor cells. MMC(TMZ)-TOC can be used for the research of cancer .

HY-RS13822

Sstr1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
Sstr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr1 Rat Pre-designed siRNA Set A Sstr1 Rat Pre-designed siRNA Set A

HY-RS13830

Sstr4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
Sstr4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr4 Mouse Pre-designed siRNA Set A Sstr4 Mouse Pre-designed siRNA Set A

HY-RS13820

SSTR1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
SSTR1 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSTR1 Human Pre-designed siRNA Set A SSTR1 Human Pre-designed siRNA Set A

HY-RS13821

Sstr1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
Sstr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr1 Mouse Pre-designed siRNA Set A Sstr1 Mouse Pre-designed siRNA Set A

HY-RS13824

Sstr2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
Sstr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr2 Mouse Pre-designed siRNA Set A Sstr2 Mouse Pre-designed siRNA Set A

Cat. No.	Product Name	Target	Research Area